Editas Medicine, Inc. (EDIT)
EDITNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$2.80
+0.2800 (+11.11%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $422.35m
- P/E
- –
- EPS, last 4 quarters
- $-0.7500
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.66 to $3.94
- Average volume
- 2.61m
- Previous close
- $2.52
Analysts
4 coveringBuy3 buy, 0 hold, 1 sell
Targets a year out average $5.67, +102.5% from here
Earnings
next estimate $-0.2100Next report
Sep 2025
+26.3%
Dec 2025
+77.8%
Mar 2026
+13.3%
Jun 2026
+50.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $7.54m | $24.74m | $2.83m | $11.89m |
| Gross profit | $7.54m | $24.74m | $2.83m | $11.89m |
| Operating income | -$24.55m | -$7.75m | -$25.00m | -$18.55m |
| Net income | -$25.12m | -$5.62m | -$24.98m | -$18.23m |
Last four quarters: revenue $47.01m, margin -157.3%, free cash flow -$120.55m
News
8 latest- Editas Medicine, Inc. Reports Third Quarter 2026 Net Loss of $23.4 millionFintel · 10 hours ago
- Editas Q3 Loss Narrows; First Dosing In EDIT-401 Cholesterol Trial On Track For 2026 RTTNews · 11 hours ago
- EDITAS MEDICINE, INC. Q3 Loss Decreases RTTNews · 13 hours ago
- Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue EstimatesZacks · 14 hours ago
- Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesZacks · 5 days ago
- EDIT Set to Begin First-in-Human Study in Hypercholesterolemia Zacks · Oct 9, 2026
- Wells Fargo Upgrades Editas Medicine to Overweight from Equal-WeightFintel · Oct 8, 2026
- Editas Advances Gene-Editing Program Into First Human Study For High Cholesterol RTTNews · Oct 8, 2026
The company
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- editasmedicine.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.